GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 109-120 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Glucagon-Like Peptide-1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes.

Rassam F; Lopez EK; Sass S; Srikulmontri T; Isaacs E; Malin J; Wattanachayakul P; Afolabi-Brown O

Jan 1, 2026Journal of arrhythmia

2026PubMedDirectly related

[New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise].

Barton A; Schattenberg JM

Jan 1, 2026Zeitschrift fur Gastroenterologie

2026PubMedDirectly related

Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.

Kassem S

Jan 1, 2026Diabetes, obesity & metabolism

2026PubMedSupporting evidence

Heart failure with a preserved ejection fraction: synergy between cardiac and extracardiac mechanisms and effects of novel therapies.

Nassiri S; Handoko ML; van de Bovenkamp AA; van Empel VPM; van Raalte DH; Eringa EC

Jan 1, 2026Heart failure reviews

2026PubMedDirectly related

Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study.

Carafa A; Sessa RL; Amendolara R; Zampetti S; Mignogna C; Sciarra F; D'Onofrio L; Risi R; Venneri MA; Cavallari I; Maddaloni E; Buzzetti R

Jan 1, 2026Acta diabetologica

2026PubMedDirectly related

Euglycaemic ketoacidosis associated with dual-acting GLP-1/GIP receptor agonist treatment following bariatric surgery.

Green D; Glynn N

Jan 1, 2026Endocrinology, diabetes & metabolism case reports

2026PubMedDirectly related

Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic.

Deas C; Uhomba L; Snow K

Jan 1, 2026Journal of health care for the poor and underserved

2026PubMedDirectly related

Adjuvant Glucagon-like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.

Cross-Najafi AA; Benavidez MC; No JJ; Ngo KC; Redpath S; Nin DZ; Schimpke SW; Myers JA; Omotosho P; Torquati A; Skertich NJ

Jan 1, 2026The Journal of surgical research

2026PubMedDirectly related

Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.

Rombach J; Hannani MT; Henriksen K; Bihlet AR; Bajaj M; He Y; Bay-Jensen AC; Thudium CS; Karsdal M

Jan 1, 2026Osteoarthritis and cartilage

2026PubMedDirectly related

Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice.

Bridges AG; Jackson T

Jan 1, 2026Clinics in dermatology

2026PubMedDirectly related

Combination pharmacotherapy for MASH: Potential synergistic approaches.

Meije DA; Holleboom AG; van de Graaf SFJ

Jan 1, 2026Biochemical pharmacology

2026PubMedSupporting evidence

Patient and healthcare professional perceptions of weight reduction in the treatment of knee osteoarthritis: A systematic literature review.

Conaghan PG; Rolland C; Frampton J; Lavoie L; Giblin K; Robinson R; Perez-Nieves M

Jan 1, 2026Osteoarthritis and cartilage open